Gland Pharma, Nippon Life India Asset Management, Shriram Fin. grant ESOPs

Gland Pharma allocated 1,100 shares to employees; Nippon Life India Asset Management approved equity share allotments, while Shriram Finance allocated 1,00,189 shares to 311 employees.


Gland Pharma, the pharmaceutical company in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announced the allocation of 1,100 fully paid-up equity shares with a nominal value of Re 1 each to eligible employees. This allocation, following the exercise of stock options under the Gland Pharma employee stock options (ESOP) scheme in 2019, increased the company’s issued, subscribed and paid-up share capital to Rs. 1,64,701,923, comprising 1,64,701,923 equity shares with a face value of Re 1.

Nippon Life India Asset Management (formerly Reliance Nippon Life Asset Management), an asset management company has approved  equity share allotments under two ESOPs.

Effective 9 October 2023, these allotments increased the issued, subscribed and paid-up equity share capital of Nippon Life India Asset Management to 62,48,77,180 equity shares, each with a face value of Rs. 10. These 83,491 equity shares rank equally with the existing shares.

The ESOP allotment committee at Shriram Finance, an Indian financial service has approved the allocation of 1,00,189 equity shares, each with a face value of Rs 10, to 311 eligible employees. These employees exercised their fresh stock options under SFL ESOS 2023 (No. 1). Consequently, the paid-up share capital of Shriram Finance increased from Rs. 3,75,34,70,830 to Rs. 3,75,44,72,720.

Comment on the Article

Please enter your comment!
Please enter your name here

4 × three =